Evolus Stock Price, News & Analysis

Evolus (NASDAQ: EOLS) will report its third quarter 2025 financial results on Wednesday, November 5, 2025 after U.S. markets close. Management will host a conference call and live webcast at 4:30 p.m. ET the same day, followed by a question-and-answer session.

Investors can join the call by dialing (877) 407-6184 (U.S.) or (201) 389-0877 (international), or listen via the live webcast on the Evolus Investor Relations page. A telephonic replay will be available at (877) 660-6853 (U.S.) or (201) 612-7415 (international) using conference number 13756397. An archived webcast will be posted at www.evolus.com.

Evolus (NASDAQ: EOLS) announced inducement equity awards for nine newly hired non‑executive employees under its 2023 Inducement Incentive Plan.

The company granted an aggregate of 24,931 non‑qualified stock options and 31,116 restricted stock units (RSUs) with a grant and vesting commencement date of October 7, 2025. The stock options carry a $6.26 exercise price (the closing price on October 7, 2025), a 10‑year term, and vest 25% on each annual anniversary over four years. The RSUs vest 25% on each annual anniversary over four years. Awards were approved by the compensation committee as inducements in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to plan and award agreement terms, including continued employment requirements for vesting.

Evolus (NASDAQ: EOLS) has appointed Dr. Benjamin Eskenazi as lead consultant for the national launch of their Evolysse™ filler line. Dr. Eskenazi, founder of Miami Beach's Avabello Aesthetics, will provide expertise and support to aesthetic providers implementing the newly FDA-approved hyaluronic acid dermal fillers.

The Evolysse™ line features innovative Cold-X™ technology for longer-lasting results and includes Evolysse™ Form and Evolysse™ Smooth, with additional products planned for launch in 2026 and 2027. This partnership demonstrates Evolus' commitment to patient safety and provider education in the aesthetic medicine field.

Evolus (NASDAQ: EOLS), a performance beauty company, has announced inducement grants to new employees under Nasdaq Listing Rule 5635(c)(4). The company granted 8,744 stock options and 15,000 RSUs to 6 new non-executive employees, and 143,403 shares and 104,603 RSUs to new CFO Tatjana Mitchell.

The non-executive employee stock options have an exercise price of $7.66 per share with a 10-year term, vesting 25% annually. Their RSUs vest 25% annually. Mitchell's options are priced at $7.61 per share, also with a 10-year term and 25% annual vesting, while her RSUs vest 50% on the third and fourth anniversaries of the grant.

Evolus (NASDAQ: EOLS), a performance beauty company, has appointed Tatjana Mitchell as its new Chief Financial Officer, effective September 8, 2025. Mitchell brings over 20 years of strategic and operational finance leadership experience, most recently serving as Senior Vice President of Corporate Finance at Experian, where she managed financial planning across six business units representing $5+ billion in revenue.

At Experian, Mitchell demonstrated success in driving double-digit organic revenue growth, executing acquisitions, and improving EBITDA margins. Her previous roles include CFO positions at Zulily, and finance leadership positions at Forever 21, Macy's, Gap Inc., and Marriott International. Mitchell holds an MBA from The Wharton School and a BS in Business Administration from Towson University.

Evolus (NASDAQ: EOLS) announced positive topline results from its U.S. pivotal study of Evolysse™ Sculpt, an injectable hyaluronic acid gel product for mid-face volume restoration. The study demonstrated statistical superiority over Restylane®-Lyft, with Evolysse™ Sculpt achieving a 90.9% responder rate compared to 83.3% for Restylane®-Lyft.

The company has submitted a Premarket Approval (PMA) application to the FDA, with approval expected in the second half of 2026. The product, manufactured using innovative Cold-X™ technology, showed a favorable safety profile with no treatment-related serious adverse events. This development marks a significant expansion beyond Evolus' existing Jeuveau® product line.

Evolus (NASDAQ: EOLS) has submitted its final Premarket Approval (PMA) application to the FDA for Evolysse™ Sculpt, an injectable hyaluronic acid gel designed for mid-face volume restoration. The submission follows completion of a pivotal clinical trial involving 304 patients comparing Evolysse™ Sculpt to Restylane®-Lyft in a double-blinded, controlled study.

The product, manufactured using innovative Cold-X™ technology, is positioned to enter the high-value mid-face dermal filler segment. FDA approval is anticipated in the second half of 2026. Evolysse™ Sculpt is expected to be the flagship product in the company's Evolysse™ collection, featuring technology that preserves the natural structure of HA molecules for long-lasting results.

Evolus (NASDAQ: EOLS), a performance beauty company, has announced the grant of 12,731 restricted stock units (RSUs) to 5 newly hired non-executive employees under its 2023 Inducement Incentive Plan. The grants were approved by the company's compensation committee with a grant date of August 7, 2025.

The RSUs will vest over a four-year period, with 25% vesting on each annual anniversary of the vesting commencement date. Continued employment is required for vesting, and the grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).

Evolus (NASDAQ: EOLS) reported Q2 2025 financial results with global net revenue of $69.4 million, up 4% year-over-year despite market headwinds. The growth was driven by the successful launch of Evolysse™, which contributed $9.7 million in revenue, and strong international performance.

The company reported a GAAP operating loss of $10.2 million and ended the quarter with $61.7 million in cash. Evolus revised its 2025 revenue guidance to $295-305 million and expects to achieve profitability in Q4 2025. The company maintains its 2028 revenue target of $700 million with projected non-GAAP operating margins of 20%.

Key operational metrics include over 16,500 total purchasing accounts, a 70% reorder rate, and 1.2 million members in the Evolus Rewards™ program. The company announced cost optimization measures expected to yield $25 million in non-GAAP operating expense savings for 2025.